|
Market Closed -
Nasdaq
21:00:00 16/01/2026 GMT
|
5-day change
|
1st Jan Change
|
|
54.59 USD
|
-0.87%
|
 |
-7.40%
|
-8.14%
|
|
01-13 |
BioMarin Pharmaceuticals Aims for Sustained Growth in 2026, Wedbush Says
|
MT
| |
12-22 |
Truist Securities Lifts BioMarin Pharmaceutical Price Target to $100 From $80, Maintains Buy Rating
|
MT
| |
12-19 |
Top Midday Gainers
|
MT
| |
12-03 |
Leerink Partners Downgrades BioMarin Pharmaceutical to Market Perform From Outperform, Adjusts PT to $60 From $82
|
MT
| |
11-06 |
BioMarin Pharmaceutical Shares Drop After Downgrade From Stifel
|
MT
| |
11-06 |
Stifel Downgrades BioMarin Pharmaceutical to Hold From Buy, Adjusts Price Target to $61 From $73
|
MT
| |
29/10/25 |
Fda accepts Biomarin's Palynziq supplemental bla for priority review to expand use to adolescents aged 12-17 with phenylketonuria
|
RE
| |
28/10/25 |
Truist Lowers Price Target on BioMarin Pharmaceutical to $80 From $90, Keeps Buy Rating
|
MT
| |
28/10/25 |
RBC Cuts Price Target on BioMarin Pharmaceutical to $66 From $70, Keeps Sector Perform Rating
|
MT
| |
28/10/25 |
Morgan Stanley Trims Price Target on BioMarin Pharmaceutical to $98 From $104, Keeps Overweight Rating
|
MT
| |
28/10/25 |
Analyst recommendations: Confluent, Crowdstrike Holdings, Fox Corporation, Oracle, Apple…
|  | |
08/09/25 |
HC Wainwright Initiates Coverage on BioMarin Pharmaceutical With Neutral Rating, $60 Price Target
|
MT
| |
05/08/25 |
UBS Adjusts Price Target on BioMarin Pharmaceutical to $114 From $113, Maintains Buy Rating
|
MT
| |
05/08/25 |
Morgan Stanley Raises Price Target on BioMarin Pharmaceutical to $104 From $96, Keeps Overweight Rating
|
MT
| |
04/08/25 |
BioMarin Pharma Q2 revenue beats estimates
|
RE
| |
25/02/25 |
Analyst recommendations: Block, Lucid, Celsius, Dun & Bradstreet, Sentinelone...
| | |
24/02/25 |
Oppenheimer Upgrades BioMarin Pharmaceutical to Outperform From Market Perform, Price Target is $98
|
MT
| |
20/02/25 |
UBS Adjusts Price Target on BioMarin Pharmaceutical to $113 From $109, Maintains Buy Rating
|
MT
| |
03/02/25 |
BofA Adjusts Price Target on BioMarin Pharmaceutical to $99 From $100
|
MT
| |
25/11/24 |
RBC Cuts Price Target on BioMarin Pharmaceutical to $70 From $80, Keeps Sector Perform Rating
|
MT
| |
15/11/24 |
Wolfe Research Initiates BioMarin Pharmaceutical at Outperform With $95 Price Target
|
MT
| |
30/10/24 |
UBS Adjusts Price Target on BioMarin Pharmaceutical to $106 From $104, Maintains Buy Rating
|
MT
| |
30/10/24 |
William Blair Downgrades BioMarin Pharmaceutical to Market Perform From Outperform
|
MT
| |
30/10/24 |
Analyst recommendations: Align, Nvidia, Crocs, PayPal, Reddit...
| | |
04/10/24 |
RBC Lowers Price Target on BioMarin Pharmaceutical to $80 From $85, Keeps Sector Perform Rating
|
MT
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
